Publications
363 publications
- Date
- Relevance
-
GVS advice SGLT-2 inhibitors
The National Health Care Institute has completed its assessment the further conditions of SGLT-2 inhibitors canagliflozin ...
-
GVS advice RZV (Shingrix®) for the prevention of herpes zoster and related post-herpetic neuralgia
Zorginstituut Nederland has completed its assessment whether the recombinant herpes zoster vaccine with adjuvant (RZV, Shingrix®) ...
-
GVS advice onosilodrostat (Isturisa®) for the treatment of endogenous Cushing syndrome
The National Health Care Institute advises the Minister to include osilodrostat on List 1A in cluster 0V04CDAO V. Osilodrostat ...
-
GVS advice avatrombopag (Doptelet®) for the treatment of thrombocytopenia
The National Health Care Institute has completed its assessment whether avatrombopag (Doptelet®) is interchangeable with a ...
-
GVS advice Vocabria® and Rekambys® for the treatment of HIV-1 infection
The National Health Care Institute has completed its assessment whether the products Rekambys® and Vocabria® can be included in ...
-
Package advice isatuximab (Sarclisa®) for the treatment of multiple myeloma
The National Health Care Institute has completed its assessment whether isatuximab (Sarclisa®) in combination with carfilzomib ...
-
GVS advice ivacaftor (Kalydeco®) extension of further conditions
Zorginstituut Nederland carried out a review to extend the further conditions for reimbursement of ivacaftor (Kalydeco®). The ...
-
GVS advice dapagliflozin (Forxiga®) extension of further condition
The National Health Care Institute has completed its assessment whether the further condition of dapagliflozin (Forxiga®) could ...
-
Package advice pertuzumab and trastuzumab (Phesgo®) for the treatment of breast cancer
Zorginstituut Nederland has completed its assessment whether the fixed combined dose of pertuzumab and trastuzumab (Phesgo®) can ...
-
Package advice onasemnogene abeparvovec (Zolgensma®) for the treatment of SMA
Zorginstituut Nederland has completed its assessment whether onasemnogene abeparvovec (Zolgensma®) for the treatment of patients ...